Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...